STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE
Authors:
- Jenny Y. ChienJCJenny Y. Chien
- Aroonrut LucksiriALAroonrut Lucksiri
- Charles S. ErnestCECharles S. Ernest
- J. Christopher GorskiJGJ. Christopher Gorski
- Steven A. WrightonSWSteven A. Wrighton
- Stephen D. HallSHStephen D. Hall
- 1 July 2006
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 34 (7) , 1208-1219
Abstract
Conventional methods to forecast CYP3A-mediated drug-drug interactions have not employed stochastic approaches that integrate pharmacokinetic (PK) variability and relevant covariates to predict inhibition in terms of probability and uncertainty. Empirical approaches to predict the extent of inhibition may not account for nonlinear or non-steady-state conditions, such as first-pass effects or accumulation of inhibitor concentration with multiple dosing. A physiologically based PK model was developed to predict the inhibition of CYP3A by ketoconazole (KTZ), using midazolam (MDZ) as the substrate. The model integrated PK models of MDZ and KTZ, in vitro inhibition kinetics of KTZ, and the variability and uncertainty associated with these parameters. This model predicted the time- and dose-dependent inhibitory effect of KTZ on MDZ oral clearance. The predictive performance of the model was validated using the results of five published KTZ-MDZ studies. The model improves the accuracy of predicting the inhibitory effect of increasing KTZ dosing on MDZ PK by incorporating a saturable KTZ efflux from the site of enzyme inhibition in the liver. The results of simulations using the model supported the KTZ dose of 400 mg once daily as the optimal regimen to achieve maximum inhibition by KTZ. Sensitivity analyses revealed that the most influential variable on the prediction of inhibition was the fractional clearance of MDZ mediated by CYP3A. The model may be used prospectively to improve the quantitative prediction of CYP3A inhibition and aid the optimization of study designs for CYP3A-mediated drug-drug interaction studies in drug development.Keywords
This publication has 46 references indexed in Scilit:
- Physiological Approaches to the Prediction of Drug-Drug Interactions in Study PopulationsCurrent Drug Metabolism, 2003
- The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activityClinical Pharmacology & Therapeutics, 2003
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003
- The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activityBritish Journal of Clinical Pharmacology, 2002
- Persistent Inhibition of CYP3A4 by Ketoconazole in Modified Caco-2 CellsPharmaceutical Research, 2000
- The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*Clinical Pharmacology & Therapeutics, 1998
- Physiological Parameter Values for Physiologically Based Pharmacokinetic ModelsToxicology and Industrial Health, 1997
- Influence of food on the pharmacokinetics of ketoconazoleAntimicrobial Agents and Chemotherapy, 1984
- Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in manJournal of Antimicrobial Chemotherapy, 1983
- Pharmacokinetics of ketoconazole in normal subjectsJournal of Antimicrobial Chemotherapy, 1981